Search results
Results From The WOW.Com Content Network
Inovio's net loss for the third quarter of 2024 was $25.2 million, or $0.89 per share, basic and dilutive, compared to a net loss of $33.9 million, or $1.52 per share, basic and dilutive, for the ...
Inovio Pharmaceuticals Inc (NASDAQ: INO) shareholders are suing the company in U.S. District Court alleging the vaccine maker misled investors by saying it came up with a coronavirus vaccine ...
Inovio Pharmaceuticals (INO) on Tuesday announced “positive” interim clinical data results of INO-4800, its experimental vaccine candidate against the novel coronavirus.Shares, however dropped ...
[7] [18] Inovio is in competition to develop a coronavirus vaccine with numerous other companies, which were conducting preclinical or early-stage human research on more than 170 vaccine candidates, as of late June. [5] In April 2020, Inovio began a Phase I trial of the COVID-19 vaccine candidate, INO-4800. [19]
Inovio Pharmaceuticals (INO) disappoints with earnings and revenue miss in the second quarter. Shares depreciate in after-hours trading. Inovio (INO) Q2 Earnings & Revenues Fall Shy of Estimates
Inovio Pharmaceuticals (INO) soared 5% in Tuesday’s after-market trading after the company announced positive interim data from a Phase 1/2a trial of DNA vaccine INO-4700 for MERS coronavirus ...
Inovio (INO) concludes enrollment in the phase I/II study on INO-5401+INO-9012 combined with Regeneron/Sanofi's Libtayo for the newly-diagnosed subjects with glioblastoma prior to the scheduled date.
2020 has been a wild ride for Inovio Pharmaceuticals (INO). Virtually unknown at the start of the year, investors’ enthusiasm for coronavirus stocks has seen the DNA vaccine specialist post year ...